资讯

MyChesCo on MSN23 小时
XyloCor Doses First Patient in Pivotal Gene Therapy Trial for Refractory Angina
KING OF PRUSSIA, PA — XyloCor Therapeutics has dosed the first patient in its Phase 2b EXACT-2 trial evaluating XC001 (encoberminogene rezmadenovec), a novel gene therapy designed to help patients ...